POLB 001 CRS patent granted in Canada

AI SummaryClose X

Poolbeg Pharma PLC has been granted a patent in Canada for its POLB 001 cancer immunotherapy-induced Cytokine Release Syndrome (CRS) treatment, strengthening its global intellectual property portfolio. This patent, which covers the use of any p38 MAPK inhibitor, including POLB 001, for preventing CRS, follows a similar grant in Australia and was expedited through the Patent Prosecution Highway. The company's IP now extends to both cancer immunotherapy-induced CRS and severe influenza across multiple jurisdictions, enhancing POLB 001's future value and appeal to potential partners, with interim data from the TOPICAL trial anticipated this summer.

Disclaimer*

UK 100

Latest directors dealings